A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis
Authors
Keywords
-
Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 27, Issue 10, Pages 1885-1897
Publisher
Informa Healthcare
Online
2011-08-18
DOI
10.1185/03007995.2011.608655
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
- (2010) C. Salliot et al. ANNALS OF THE RHEUMATIC DISEASES
- The Japanese experience with biologic therapies for rheumatoid arthritis
- (2010) Tsutomu Takeuchi et al. Nature Reviews Rheumatology
- Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
- (2010) Gert J.D. Bergman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- (2008) J Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
- (2008) Jonathan Kay et al. ARTHRITIS AND RHEUMATISM
- Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
- (2008) Alberto Alonso-Ruiz et al. BMC MUSCULOSKELETAL DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now